1. Comprehensive Cervical Cancer Prevention and Control. Programs guidance for countries, UNFPA, 2011.eeca.unfpa.org/.../ENGLISH%20Cervical%20Cancer%20Guidance.pdf.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. GLOBOCAN 2008 v2.0 (accessed Aug 2012), Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. National Institutes of Health. Cervical Cancer. NIH Consensus Statement. 1996;14(1):1-38.)and 14th for all cancers affecting U.S. women. (National Cancer Institute (NCI). (2010, Nov. Last reviewed). Cancer advances in focus: cervical cancer.
5. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2014.
6. Krishnan S, Madsen E, Porterfield D, Varghese B. Advancing Cervical Cancer Prevention in India: Implementation Science Priorities. Oncologist. 2013;18(12):1285-1297.
7. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in India 2007.
8. Singh N. HPV and Cervical cancer - prospects for prevention through vaccination. Indian J Med Paediatr Oncol. 2005;26(1):20-23.
9. Institute for Health Metrics and Evaluation. The challenge ahead: Progress in breast and cervical cancer. Institute of Health Metrics and Evaluation, 2011.
10. Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore. Br J Cancer. 1995;71(6):1348-1352.
11. Frumovitz, M. Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis. (2013).
12. American Cancer Society (ACS). (2014, Jan. - Last revised).Cervical cancer: detailed guide.
13. Wright, JD. (2014, May. - Last updated). Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention.
14. National Cancer Institute (NCI). (2012, Mar. - Last reviewed). Fact sheet: HPV and cancer.
15. USPSTF. (2012). Screening for cervical cancer.
16. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam S, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. 2011.
17. Screening for Cervical Cancer: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 11-05156-EF-3, March 2012.
18. Clinical Summary: Cervical Cancer: Screening. U.S. Preventive Services Task Force. October 2014.
19. Howlder N, Noone AM, Krapcho M, Garshell J, Miller D, et al. SEER cancer statistics review, 1975-201., National Cancer Institute, Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
20. vanNagell JR, Donaldson ES, Wood EG (1978). Urinary tract involvement by invasive cervical carcinoma. In Buchsbaum HJ, Schmidt JD (eds): Gynecologic and Obstetric Urology. Philadelphia, WB Saunders, 1978.
21. Buchsbaum HJ. Extrapelvic lymph node metastases in cervical carcinoma. Am J Obstet Gynecol. 1979;133(7):814-824.
22. Henriksen E. Lymphatic spread of cervix and corpus carcinoma. Am J O bstet Gynecol. 1949;58(5):924-942.
23. Lee YN, Wang KL, Lin MH, et al. Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases. Gynecol Oncol. 1989;32(2):135-142.
24. Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol. 1998;51(2):96-103.
25. Sevin BU, Nadji M, Averette HE, Hilsenbeck S, Smith D, Lampe B. Microinvasive carcinoma of the cervix. Cancer. 1992;70(8):2121-2128.
26. Kindermann J, Jabursch HP. The spread of squamous cell carcinoma of the uterine cervix into the blood vessels. Arch Gynecol. 1972;212(1):1-8.
27. Barter JF, Soong SJ, Hatch KD, Orr JW, Shingleton HM. Diagnosis and treatment of pulmonary metastases from cervical carcinoma. Gynecol Oncol. 1990;38(3):347-351.
28. Carlson V, Delclos L, Fletcher GH. Distant metastases in squamous-cell carcinoma of the uterine cervix. Radiology. 1967;88(5):961-966.
29. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107-108.
30. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103-104.
31. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. V 3.2013.
32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer Version 1.2015.
33. Frederick P, Whitworth J, Alvarez R. Glob. libr. women's med.
34. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-1143.
35. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-1153.
36. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154-1161.
37. Perez CA, Grigsby PW, Camel HM, Galakatos AE, Mutch D, Lockett MA. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterinecervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 1995;31(4):703-716.
38. Perez CA, Grigsby PW, Nene SM, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer. 1992;69(11):2796-2806.
39. Estape R, Angioli R. Surgical management of advanced and recurrent cervical cancer. Semin Surg Oncol. 1999;16(3):236-241.
40. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (Review). Oncol Lett. 2010;1(1):3-11.
41. Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1992;24(2):197-204.
42. Friedlander M, Grogan M, U.S. Preventative Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 2002;7(4):342-347.
43. US Food and Drug Administration (2014). FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer [news release].
44. Lowes R (2014). FDA OKs bevacizumab (Avastin) for late-stage cervical cancer. Medscape Medical News [serial online].
45. Tewari KS, Sill MW, Long HJ III, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743.
46. Mulcahy N. Bevacizumab changes practice in advanced cervical cancer. Medscape Medical News [serial online]. February 19, 2014.
47. Chustecka Z. Bevacizumab Prolongs Survival in Advanced Cervical Cancer. Medscape [serial online]. 2013.
48. Tewari KS, Sill M, Long HJ,Ramondetta LM, Landrum LM, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. Asco University, 2013.
49. Al-Halal H, Kezouh A, Abenhaim HA. Incidence and obstetrical outcomes of cervical intraepithelial neoplasia and cervical cancer in pregnancy: a population-based study on 8.8 million births. Arch Gynecol Obstet. 2013;287(2):245-250.
50. Amant F, Brepoels L, Halaska MJ, Gziri MM, Calsteren KV. Gynaecologic cancer complicating pregnancy: an overview. Best Pract Res Clin Obstet Gynaecol. 2010;24(1):61-79.
51. Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. Am J Obstet Gynecol. 2008;199(1):10-18.
52. Morice P, Narducci F, Mathevet P, et al. French Working Group on Gynecological Cancers in Pregnancy; French recommendations on the management of invasive cervical cancer during pregnancy. Int J Gynecol Cancer. 2009;19(9):1638-1641.
53. Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. Lancet. 2012;379(9815):558-569.
54. Paraskevaidis E, Koliopoulos G, Kalantaridou S, et al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum. Eur J Obstet Gynecol Reprod Biol. 2002;104(1):67-69.
55. Jain AG, Higgins RV, Boyle MJ. Management of low-grade squamous intraepithelial lesions during pregnancy. Am J Obstet Gynecol. 1997;177(2):298-302.
56. Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009.
57. Plante M, Renaud MC, Francois H, Roy M. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecol Oncol. 2004;94(3):614-623.
58. Karateke A, Cam C, Celik C, et al. Radical trachelectomy in late pregnancy: is it an option? Eur J Obstet Gynecol Reprod Biol. 2010;152(1):112-113.
59. Ungar L, Smith JR, Palfalvi L, Del Priore G. Abdominal radical trachelectomy during pregnancy to preserve pregnancy and fertility. Obstet Gynecol. 2006;108(3 Pt 2):811-814.
60. Rob L, Skapa P, Robova H. Fertility-sparing surgery in patients with cervical cancer. Lancet Oncol. 2011;12(2):192-200.
61. Karam A, Feldman N, Holschneider CH. Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy. Nat Clin Pract Oncol. 2007;4(6):375-380.
62. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105(2):299-303.
63. Zagouri F, Sergentanis TN, Chrysikos D, Bartsch R. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;121(2 Pt 1):337-343.
64. Han SN, Gziri MM, Van Calsteren K, Amant F. Is chemotherapy during the first trimester of pregnancy really safe? Int J Cancer. 2013;132(7):1728.
65. Amant F, Van Calsteren K, Halaska MJ, et al. 2012). Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13(3):256-264.
66. Perrin KK, Daley EM, Naoom SF, et al. Women's reactions to HPV diagnosis: insights from in-depth interviews. Women Health. 2006;43(2):93-110.
67. Herzog TJ, Wright JD. The impact of cervical cancer on quality of life - the components and means for management. Gynecol Oncol. 2007;107(3):572-577.
68. Linnehan MJ, Groce NE. Counseling and educational interventions for women with genital human papillomavirus infection. AIDS Patient Care STDS. 2000;14(8):439-445.
69. Carter J, Stabile C, Gunn A, Sonoda Y. The psychical consequences of gynecologic cancer surgery and their impact on sexual, emotional, and quality of life issues. J Sex Med. 2013;10:21-34.
70. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril. 2013;100(4):916-921.
71. Turan V, Oktay K. Sexual and fertility adverse effects associated with chemotherapy treatment in women. Expert Opin Drug Saf. 2014;13(6):775-783.
72. Sekse RJ, Gjengedal E, Raheim M. Living in a changed female body after gynecological cancer. Health Care Women Int. 2013;34(1):14-33.
73. Romagnolo C. Quality of life in gynaecological oncology. Clin Exp Obstet Gynecol. 1991;18(3):203-205.
74. Bifulco G, De Rosa N, Tornesello ML, et al. Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. Gynecol Oncol. 2012;124(3):444-451.
75. Tierney DK. Sexuality: a quality-of-life issue for cancer survivors. Semin Oncol Nurs. 2008;24(2):71-79.
76. Lammerink E, de Bock G, Pras E, Reyners A, Mouritis M. Sexual functioning of cervical cancer survivors: a review with a female perspective. Maturitas. 2012;72(4):296-304.
77. Abbott-Anderson K, Kwekeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol. 2012;124(3):477-489.
78. Simonelli LE, Pasipanodya E. Health disparities in unmet support needs of women with gynecologic cancer: an exploratory study. J Psycosoc Oncol. 2014;32(4):727-734.
79. National Cancer Institute (NCI). (2011, Dec. - Last reviewed). Fact sheet: human papillomavirus (HPV) vaccines.
80. CDC. FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV 4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR, 2010; 59(20):630-632.
81. Lauri Markowitz, Eileen F. Dunne, Herschel W. Lawson, Harrell Chesson, Elizabeth R. Unger. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 2007;56(RR-2):1-24.
82. CDC (2011). Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males-Advisory Committee on Immunization Practices (ACIP). MMWR, December 23 2011;60(50):1705-1708.
83. Carrington C. Oral targeted therapy for cancer. Australian Prescriber. 2015;38(5):171-176.
84. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.